T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...

Ruxolitinib phosphate is under clinical development by Incyte and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome.

CAR T-cell therapy represents a groundbreaking advancement in the field of oncology, particularly in the treatment of certain types of blood cancers such as leukemia and lymphoma. This innovative ...

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit ...

Acloproxalap (ADX-629) is under development for the treatment of plaque psoriasis, atopic (allergic) asthma, obesity, acute alcoholic hepatitis, cytokine storm, ethanol toxicity, minimal change ...

1Genentech Inc., South San Francisco, California.

The UK's Poolbeg Pharma has disclosed that it is in talks over a possible combination with Hookipa, an Austrian biotech that ...

INR:3550. the daily life of the immortal king season 5 release date Breaking news! Chinese scientists reveal the mechani ...

The following is a summary of “REmoval of cytokines during CArdiac surgery (RECCAS): a randomised controlled trial,” published in the December 2024 issue of Critical Care by Hohn et al.

The festive season may be a chance to rest up and recharge—but tell that to biotech dealmakers, who have been as busy as ever ...

The study showed that all doses of POLB 001 significantly reduced clinically observed Cytokine Release Syndrome (CRS) scores, reinforcing its potential in preventing and treating cancer ...